Literature DB >> 11401550

The 2.7 A crystal structure of the activated FERM domain of moesin: an analysis of structural changes on activation.

S D Edwards1, N H Keep.   

Abstract

Moesin binds to a large range of proteins through its N terminal FERM (band 4.1, ezrin, radixin, moesin) domain. In full-length moesin isolated from cells, this binding is masked by binding to the C-terminal domain of moesin (C-ERMAD). Activation takes place by phosphorylation of Thr 558 in the C-ERMAD, which releases the C-ERMAD. A recently determined crystal structure of a noncovalent complex of the FERM and C-ERMAD domains showed for the first time that the structure of the FERM domain consists of three subdomains, each of which is similar to known structures. The structure reported here also contains a unique 47-residue helix pointing away from the FERM domain at the start of the alpha domain, in agreement with secondary structure predictions. Removal of the C-ERMAD does not result in a huge rearrangement of the FERM domain, but comparison with the activated radixin structure shows a consistent set of small changes. Not surprisingly, the exposed C-ERMAD binding area interacts in crystal contacts. More interestingly, a negatively charged peptide binds to the inositol site in a crystal contact and causes a greater conformational change in the structure than inositol.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401550     DOI: 10.1021/bi010419h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  Characterization of a novel intracellular heparanase that has a FERM domain.

Authors:  Karen J Bame; Indumati Venkatesan; Jean Dehdashti; Jeffrey McFarlane; Rebecca Burfeind
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

2.  FERM domain interaction promotes FAK signaling.

Authors:  Jill M Dunty; Veronica Gabarra-Niecko; Michelle L King; Derek F J Ceccarelli; Michael J Eck; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain.

Authors:  Qianzhi Li; Mark R Nance; Rima Kulikauskas; Kevin Nyberg; Richard Fehon; P Andrew Karplus; Anthony Bretscher; John J G Tesmer
Journal:  J Mol Biol       Date:  2006-10-26       Impact factor: 5.469

4.  Structure of dimerized radixin FERM domain suggests a novel masking motif in C-terminal residues 295-304.

Authors:  Ken Kitano; Fumie Yusa; Toshio Hakoshima
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-03-25

5.  Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.

Authors:  S D Yogesha; Andrew J Sharff; Marco Giovannini; Gerard Bricogne; Tina Izard
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

Review 6.  Emerging role for ERM proteins in cell adhesion and migration.

Authors:  Monique Arpin; Dafne Chirivino; Alexandra Naba; Ingrid Zwaenepoel
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

Review 7.  Polyphosphoinositide-Binding Domains: Insights from Peripheral Membrane and Lipid-Transfer Proteins.

Authors:  Joshua G Pemberton; Tamas Balla
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 8.  Cellular and molecular interactions of phosphoinositides and peripheral proteins.

Authors:  Robert V Stahelin; Jordan L Scott; Cary T Frick
Journal:  Chem Phys Lipids       Date:  2014-02-17       Impact factor: 3.329

Review 9.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

10.  Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2.

Authors:  Nathalie Meurice; Lei Wang; Christopher A Lipinski; Zhongbo Yang; Christopher Hulme; Joseph C Loftus
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.